ClinicalTrials.gg
Active, not recruitingNCT04523272Updated Oct 15, 2024

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

A Phase 3 interventional study of TQB2450 and Anlotinib in Advanced Renal Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 39 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Kidney Neoplasms with a site in China — 47 open to participants now, 51 under way, 3 of them phase 3. Kidney Neoplasms · China.

Enrollment
6th of 50
528 · median 123
Started
2020
the only one that year
Phase 3
6 of 68
1 open now
Primary completion
2025-06
later than 5 of 50 live
Registered
16th of 68
by date

Among the 68 studies in Kidney Neoplasms with a site in China, this one is the 6th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2020, is one of 6 in phase 3, reaches primary completion later than 5 of the 50 other live ones, and was the 16th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

47 of the 68 studies in Kidney Neoplasms with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Kidney Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.

03

Conditions studied

  • Advanced Renal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Histopathologically confirmed renal clear cell cancer, including advanced renal cell carcinoma with clear cell components.

      1. Has not receiving systemic therapy for local advanced/ disease. 3. At least has one . 4. (ECOG) performance status of 0 to 1; ≥ 3 months.
      1. Adequate laboratory indicators. 6. Agree to provide at least 5 slices tumor tissue samples for biomarker detection.
      1. Serum or urine pregnancy tests are negative within 7 days before randomization; Men and women should agree to use effective during the study period and after the end of the study period within 6 months.
      1. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

    1. Has symptomatic central nervous system (CNS) disease and / or cancerous meningitis, pia mater disease.

      1. Has received anti-angiogenesis targeted therapy or targeted and PD-L1 immunotherapy.
      1. Has active virus, bacteria, fungal infection; Cardiovascular and cerebrovascular diseases; Gastrointestinal abnormalities; Immunodeficiency; Bleeding risk; Lung disease; Neurological or psychiatric disorders.
      1. Has participated in other clinical trials within 30 days before randomization.
      1. Has received attenuated within 28 days before randomization or planned to received attenuated live vaccine during the study period.
      1. Pregnant or lactating women. 7. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
528 participants (actual)

Study arms

  • Experimental
    TQB2450 + Anlotinib

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450 · Drug: Anlotinib

  • Active comparator
    Sunitinib Malate Capsules

    Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).

    Drug: Sunitinib

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • A multi-target receptor tyrosine kinase inhibitor.

  • A multi-target receptor tyrosine kinase inhibitor.

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) evaluated by Independent Review Committee(IRC)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.

    Time frame: up to 60 weeks

Secondary outcomes

  1. Progression free survival (PFS) evaluated by investigator

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator.

    Time frame: up to 60 weeks

  2. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 60 weeks

  3. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 60 weeks

  4. Duration of response(DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 60 weeks

  5. Progression-free survival at 12 months

    Percentage of participants whose PFS has achieved at least 12 months.

    Time frame: up to 12 months

  6. Overall survival at 12 months

    Percentage of participants whose OS has achieved at least 12 months.

    Time frame: up to 12 months

  7. Overall survival at 24 months

    Percentage of participants whose OS has achieved at least 24 months.

    Time frame: up to 24 months

07

Study locations

39 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Jun 2025, 58 months after the start.

Of 22 phase 3 interventional studies under Kidney Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 89. This study's planned 58 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2020
First posted
Aug 21, 2020
StartActual
Aug 25, 2020
Primary completionEst.
Jun 2025
CompletionEst.
Dec 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04523272
Responsible party
Sponsor
First posted
Aug 21, 2020
Start date
Aug 25, 2020
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benmelstobart

Start the discussion